Introduction to Animal Models of Wound Healing Disorders

Wound healing impairment refers to the delayed or incomplete resolution of tissue repair following injury, commonly observed in pathological conditions such as diabetes, infection, aging, ischemia, and immune dysfunction. Its key features include persistent inflammation, inadequate angiogenesis, impaired fibroblast function, abnormal collagen deposition, and delayed epithelial regeneration. Animal models are typically established through methods such as diabetes induction (using STZ‑treated or db/db mice), local ischemia, bacterial infection, or large‑area full‑thickness skin defects, thereby mimicking the pathophysiological processes seen in clinical chronic nonhealing wounds. These models often exhibit hallmark characteristics, including slowed wound closure, insufficient granulation tissue formation, reduced angiogenesis, and sustained elevation of proinflammatory cytokines.

Service Advantages of the Aniphe BioLablogical Animal Model Platform for Wound Healing Disorders

Aniphe BioLab has established a comprehensive animal model platform for wound‑healing disorders, capable of replicating various chronic, hard‑to‑heal wounds associated with diabetes, ischemia, and infection, thereby providing robust preclinical support for research into wound‑repair mechanisms and the development of innovative therapies.

	Modeling is stable and reliable. A standardized modeling workflow ensures that the delayed wound-healing phenotype is stable and highly reproducible.
	The evaluation system has been improved. It enables multidimensional evaluation, including wound closure rate, granulation tissue formation, angiogenesis, collagen deposition, and inflammatory cytokine assays.
	Adaptable to the development of multiple product categories Supports efficacy validation of drugs, growth factors, stem cells, exosomes, biomaterials, and tissue-engineered products.
	Comprehensive testing capabilities We offer wound imaging analysis, histopathology, immunohistochemistry, and molecular biology testing services.
	One-stop project services Covering the entire process, from model construction and dosing regimen design to sample analysis, data interpretation, and efficacy evaluation.

Modeling cycle	1–3 weeks
Laboratory animals	db/db mice, C57BL/6‑STZ diabetic mice, SD/Wistar diabetic rats
Positive drug	Standard clinical treatments: moist dressings, recombinant human epidermal growth factor (rhEGF), platelet-derived growth factor (PDGF‑BB/becaplermin), platelet-rich plasma (PRP), silver‑ion dressings, or silver sulfadiazine. Experimentally positive drugs include vascular endothelial growth factor (VEGF), stem cells (adipose-derived mesenchymal stem cells, umbilical cord‑derived mesenchymal stem cells), growth factor–eluting stents, and antioxidants (such as curcumin and N‑acetylcysteine), among others.
Application areas	Pathological mechanisms of diabetic ulcers and pressure sores (inflammation, angiogenesis, and matrix metalloproteinase balance); pharmacological evaluation of novel wound-healing agents, growth factor formulations, and biomaterial scaffolds; antimicrobial and debridement strategies for infected wounds; preclinical validation of physical therapies (negative-pressure wound therapy, hyperbaric oxygen therapy, low-level laser therapy); translational research on skin regeneration, tissue-engineered skin substitutes, and stem cell therapies.

Construction of an Animal Model of Wound Healing Impairment

A wound‑healing impairment model was established by combining diabetes with full‑thickness skin defects. First, a stable hyperglycemic state was induced in mice via intraperitoneal injection of streptozotocin (STZ) or by using db/db diabetic mice; once blood glucose levels consistently met the model criteria, standardized full‑thickness skin defects (typically 6–10 mm in diameter) were created on the dorsal surface. The epidermis and dermis were excised down to the subcutaneous tissue, thereby mimicking clinically relevant chronic, hard‑to‑heal wounds. Because prolonged hyperglycemia leads to sustained inflammatory responses, impaired angiogenesis, diminished fibroblast function, and reduced collagen synthesis, the model animals exhibit hallmark features such as delayed wound closure, inadequate granulation tissue formation, and impaired re‑epithelialization. This model effectively recapitulates the pathophysiological processes of chronic, non‑healing wounds like diabetic foot ulcers and is widely employed for investigating wound‑repair mechanisms and for preclinical efficacy evaluations of therapeutics, growth factors, stem cells, exosomes, and tissue‑engineering materials.